Reading Time: < 1 minuteCoverage by Oliver Longstaff for Pα+, edited by Josh Hardman. Last month, we learned that
Reading Time: 5 minutesIn this Issue California’s Psychedelic Research Bottleneck Ends Today Letter to the Editor: Neşe Devenot
Reading Time: < 1 minuteIndependent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: 3 minutesIn this Issue Lykos Insiders, Affiliates, Respond to Critics Might FDA Miss Its August 11th
Reading Time: 3 minutesFacilitator Licensing & TrainingDORA’s first set of rules, released in April, mark the first rules
Reading Time: 5 minutesHardman: So you originally were focusing on Sweden, but now you have broadened that remit
Reading Time: < 1 minuteIn this Issue Phase 2 Study of Oral Ketamine for Depression Lauded by Media and
Reading Time: 4 minutesThis was the question directed to state regulators from the chair of the Natural Medicine
Reading Time: < 1 minuteEarlier this month, the National Institute for Health and Care Excellence (NICE), which stipulates which
Reading Time: 6 minutesLongstaff: It seems a case then with standards, particularly when it comes to the individual